Quick answer: Personalized mRNA cancer vaccines require small-batch, fast-turnaround manufacturing that traditional plasmid-based workflows can't support. Two plasmid-free, in-vitro DNA amplification methods — rolling circle amplification (RCA) and PCR-based synthetic DNA templates (SDT) — cut template preparation from 1–4 weeks down to 24–48 hours, without sacrificing mRNA quality. Combined with lightweight downstream tools (cell-free DNA amplification kits, rapid affinity purification, pre-encapsulated LNPs), total production cycles can now fall under 3 weeks.

Key Takeaways

●       The problem: Traditional plasmid-based mRNA manufacturing takes 6–8 weeks total (3–4 weeks for plasmid template prep alone), which is too slow for personalized tumor vaccines that must be manufactured per-patient.

●       The clinical driver: Moderna/Merck's Intismeran (mRNA-4157/V940) cut post-surgical recurrence risk by 49% in high-risk melanoma, the first personalized cancer vaccine to show long-term survival benefit — intensifying industry pressure to manufacture faster.

●       Solution 1 — RCA (USTAT platform, Pfizer, 2026): A single-tube, plasmid-free process (RCA amplification → enzymatic linearization → in vitro transcription) that goes from circular DNA template to finished mRNA in 48 hours, cutting cycle time by 90%+ versus plasmid methods.

●       Solution 2 — PCR/SDT (BioNTech, 2022): A 3-step assembly-PCR method that builds a linear transcription template from synthetic oligonucleotides in 24 hours — ideal for early-stage neoantigen screening, with antigen presentation function equivalent to plasmid-derived mRNA.

●       The bottleneck beyond templates: Full-cycle acceleration also requires faster mRNA purification and LNP encapsulation — not just faster DNA template prep.

●       Commercial solution: Hzymes Biotech offers a lightweight mRNA production package — cell-free DNA amplification, degenerate enzymatic IVT, rapid affinity chromatography kits, and pre-encapsulated LNPs, that help shorten the overall production cycle to around 3 weeks through tailored process and product combinations.

Why Personalized Tumor Vaccines Need Faster Manufacturing

2026 marks mRNA technology's shift from emergency-use application to full multi-scenario commercialization. In China, preventive mRNA vaccine pipelines are hitting milestones: Hualan Biological's influenza mRNA vaccine became the first domestic mRNA flu candidate accepted for IND review by China's CDE, and Abogen Biosciences' shingles vaccine ABO1108 entered global-leading Phase III trials.

At the same time, mRNA is expanding from prevention into therapeutic oncology:

●       In vivo CAR-mRNA delivered via lipid nanoparticles (LNP) generates CAR-expressing immune cells directly inside the body, simplifying traditional CAR-T manufacturing.

●       Personalized mRNA tumor vaccines — precisely targeted, low-toxicity, and patient-specific — are considered one of the most promising next-generation oncology platforms.

Clinical results are validating this direction. Moderna and Merck's intismeran autogene (mRNA-4157/V940) reduced the risk of recurrence or death by 49% in high-risk melanoma patients in the Phase 2b KEYNOTE-942 trial, supporting the potential of personalized mRNA cancer vaccines. The program has since advanced into Phase 3 clinical development, further reinforcing the industry's growing confidence in mRNA-based personalized cancer vaccines.

The manufacturing implication: because each personalized vaccine encodes a patient's unique tumor neoantigens, it cannot be mass-produced in advance. It must be manufactured in small batches, on a fast turnaround, per patient — which is why compressing the mRNA production cycle has become a top industry priority.

The Bottleneck: Traditional Plasmid-Based mRNA Production

In conventional mRNA manufacturing, the plasmid DNA template step alone involves more than a dozen operations:

Gene synthesis → vector cloning → bacterial transformation → fermentation expansion → plasmid purification → enzymatic linearization

This single step takes 3–4 weeks. Add in vitro transcription (IVT), mRNA purification, and LNP encapsulation, and the total delivery cycle reaches 6–8 weeks — far too slow for personalized, per-patient vaccines.

The emerging fix: skip plasmid cloning and bacterial fermentation entirely by amplifying the DNA template directly in vitro. Two methods are leading this shift — RCA and PCR-based amplification.

Method 1: RCA (Rolling Circle Amplification) — The USTAT Single-Tube Platform

What it is: In April 2026, a Pfizer research team published USTAT (Unified Sequential Template Amplification and Transcription) in npj Vaccines (a Nature-family journal) — currently the most industrially mature RCA-based mRNA manufacturing platform.

How it works: USTAT eliminates bacterial fermentation entirely by running three steps sequentially in a single reaction tube, with no intermediate purification:

●       1. RCA isothermal amplification of a minimal circular DNA template (containing only T7 promoter, UTRs, ORF, and poly-A tail)

●       2. Type IIS restriction enzyme linearization

●       3. In vitro transcription (IVT)

 Figure: Schematic workflow of USTAT for fully synthetic mRNA manufacturing

A key innovation was optimizing Golden Gate assembly — replacing the T7 DNA ligase, adjusting fragment molar ratios, and adding a 1,2-propanediol enhancer — which raised assembly efficiency from a standard 8–10% to 48%.

Figure: Impact of eliminating intermediate purification on product quality

Figure: Head-to-head comparison of key quality attributes of the final mRNA products

USTAT Performance Data

Notable finding: removing the intermediate purification step between RCA and linearization didn't just save time — it improved product quality by avoiding DNA shearing damage and reducing non-specific DNA byproducts.

Best for: Manufacturers seeking a fully integrated, industrial-scale, plasmid-free process for personalized tumor vaccine production with consistent quality and scalable performance.

Method 2: PCR Direct Amplification — Synthetic DNA Templates (SDT)

What it is: As early as 2022, a BioNTech team validated a synthetic DNA template (SDT) approach using assembly PCR (aPCR) — one of the earliest published demonstrations that PCR-amplified templates can fully replace plasmid DNA for mRNA production.

How it works:

●       1. Three chemically synthesized single-stranded oligonucleotides are combined

●       2. One-step assembly PCR (aPCR) stitches them into a complete linear template (T7 promoter + 5'/3' UTRs + antigen-coding sequence)

●       3. Simple purification → direct use in in vitro transcription

This bypasses plasmid cloning and bacterial culture entirely.

Figure: Comparison of SDT and plasmid DNA template (PDT) manufacturing workflows

Figure: Comparison of key quality attributes of DNA templates and mRNA products

SDT vs. Plasmid (PDT) Workflow Comparison

Figure: Head-to-head validation of antigen presentation activity

Figure: Rapid screening of neoantigen immunogenicity

Real-world validation: The BioNTech team used SDT to screen 4 candidate melanoma neoantigens, completing the entire immunogenicity screen in just days and identifying 3 immunogenic neoantigens — demonstrating SDT's value for rapid early-stage target discovery.

Best for: Early-stage R&D and rapid neoantigen screening, where speed and reagent accessibility matter more than large-scale output.

RCA vs. PCR: Which Plasmid-Free Method Fits Your Use Case?

Beyond the Template: Full-Cycle Lightweight mRNA Manufacturing

Template preparation is only one bottleneck. Truly scalable personalized vaccine manufacturing requires accelerating every downstream step — mRNA purification and LNP encapsulation included.

Hzymes Biotech Lightweight mRNA Production Solution

What it does: Compresses full-cycle mRNA vaccine production from the traditional 6–8 weeks down to under 3 weeks, covering both template generation and downstream processing. 

Full service overview: mRNA CRO Service

Core components:

Cell-free DNA amplification process — flexible, plasmid-free template generation tailored to the customer's sequence, production requirements, and application needs. The specific amplification method and process conditions are developed and optimized based on the individual project rather than following a fixed workflow.

Enzymatic/degenerate IVT process — a flexible in vitro transcription strategy that can be developed and optimized according to the customer's sequence, production requirements, and application needs.

Rapid affinity chromatography kits — mRNA purification for small-scale applications (μg–mg), reducing purification time from approximately 1–2 days with conventional chromatography workflows to 0.5–2 hours. Available as HBP005016 and HBP005017.

Pre-encapsulated LNP products — ready-to-use lipid nanoparticle formulations for streamlined formulation workflows, with product-specific options and QC data available for different applications.

Who it's for: Biotech and pharma teams developing personalized mRNA tumor vaccines or early-stage mRNA candidates that need fast, small-batch, GMP-relevant production without building out full in-house infrastructure.

Key Benefit at a Glance

Frequently Asked Questions

Why can't personalized tumor vaccines use traditional plasmid-based mRNA manufacturing? 

Because each vaccine is designed around an individual patient's unique tumor neoantigens, it can't be mass-produced in advance. Traditional plasmid manufacturing takes 6–8 weeks total, which is too slow for a per-patient production model that needs to move from biopsy to injectable vaccine quickly.

What is plasmid-free mRNA manufacturing? 

It is a manufacturing approach that eliminates the need for establishing a multi-tier bacterial cell bank and associated fermentation steps required for conventional plasmid DNA production. By generating the DNA transcription template directly in vitro, using a suitable amplification strategy such as RCA, PCR-based methods, or other project-specific approaches, the process can simplify upstream template preparation and potentially shorten the overall manufacturing timeline.

What is the USTAT platform? 

USTAT (Unified Sequential Template Amplification and Transcription) is a single-tube, plasmid-free mRNA manufacturing platform published by a Pfizer research team in npj Vaccines in April 2026. It combines RCA amplification, enzymatic linearization, and in vitro transcription in one tube with no intermediate purification, producing mRNA from a circular DNA template in 48 hours.

What is a synthetic DNA template (SDT)? 

SDT is a PCR-based method, first validated by BioNTech in 2022, that assembles three synthetic oligonucleotides via one-step assembly PCR into a complete linear mRNA transcription template — ready for in vitro transcription within 24 hours, without any plasmid cloning.

Is plasmid-free mRNA (RCA or PCR-derived) as good quality as plasmid-derived mRNA? 

Yes, based on published data. Both USTAT (RCA) and SDT (PCR) mRNA show sequence fidelity matching plasmid-derived mRNA (99.93% RNA-seq alignment, no indel mutations), and functional equivalence in antigen presentation and T-cell activation assays. USTAT-derived mRNA has shown higher protein expression in some assays.

How much can lightweight mRNA manufacturing reduce total production time? 

Combining plasmid-free template amplification with accelerated downstream purification and pre-encapsulated LNPs can compress total production cycles from the traditional 6–8 weeks to under 3 weeks, as demonstrated by solutions such as Hzymes’ lightweight mRNA production package.

What clinical evidence supports personalized mRNA cancer vaccines? 

Moderna and Merck's intismeran autogene (mRNA-4157/V940), combined with pembrolizumab, has demonstrated positive Phase 3 clinical results in patients with high-risk melanoma, providing further clinical validation for personalized mRNA cancer vaccines and supporting their potential as a new treatment approach in oncology.

References

1. Ghosh S, Simms CL, Rohrer SD, et al. USTAT: Unified Sequential Template Amplification and Transcription—a fully synthetic mRNA manufacturing platform. npj Vaccines. 2026;11:112. https://doi.org/10.1038/s41541-026-01434-8

2. de Mey W, De Schrijver P, Autaers D, et al. A synthetic DNA template for fast manufacturing of versatile single epitope mRNA. Molecular Therapy: Nucleic Acids. 2022;29:943-954. https://doi.org/10.1016/j.omtn.2022.08.021